

# GLP-1 receptor - Do we really know what we're looking at?

---

**Homolak, Jan; Babić Perhoč, Ana; Knezović, Ana; Osmanović Barilar, Jelena; Šalković-Petrišić, Melita**

*Source / Izvornik:* **Acta Histochemica, 2021, 123**

**Journal article, Accepted version**

**Rad u časopisu, Završna verzija rukopisa prihvaćena za objavljivanje (postprint)**

<https://doi.org/10.1016/j.acthis.2021.151732>

*Permanent link / Trajna poveznica:* <https://urn.nsk.hr/urn:nbn:hr:105:200103>

*Rights / Prava:* [In copyright](#) / [Zaštićeno autorskim pravom.](#)

*Download date / Datum preuzimanja:* **2024-07-09**



*Repository / Repozitorij:*

[Dr Med - University of Zagreb School of Medicine  
Digital Repository](#)



1 **GLP-1 receptor – do we really know what we're looking at?**

2

3 Jan Homolak<sup>1,2</sup>, Ana Babic Perhoc<sup>1,2</sup>, Ana Knezovic<sup>1,2</sup>, Jelena Osmanovic Barilar<sup>1,2</sup>, Melita Salkovic-  
4 Petrisic<sup>1,2</sup>

5 <sup>1</sup>Department of Pharmacology, University of Zagreb School of Medicine, Zagreb, Croatia

6 <sup>2</sup>Croatian Institute for Brain Research, University of Zagreb School of Medicine, Zagreb, Croatia

7

8

9 Corresponding Author:

10 Jan Homolak, MD

11 Department of Pharmacology,

12 University of Zagreb School of Medicine,

13 Zagreb, Croatia

14 +385 91 9411 468

15 [homolakjan@gmail.com](mailto:homolakjan@gmail.com)

16 [\(jan.homolak@mef.hr\)](mailto:jan.homolak@mef.hr)

17

18

19 Dear Editors,

20 We read with great interest a recent comprehensive review covering the knowns and the unknowns  
21 of glucagon-like peptide-1 (GLP-1) by McLean et al. (McLean et al., 2020). GLP-1 is best known for its  
22 incretin effects first described in the 1980s that provided strong foundations for the development of  
23 GLP-1 targeting drugs and revolutionized pharmacotherapy of insulin resistance in the 2000s (Drucker  
24 et al., 2017). Nevertheless, as evident from (McLean et al., 2020), we can expect that the glory days of  
25 GLP-1 are far from over and that this incretin is going to be even more important for the doctors of  
26 tomorrow based on many of its relevant actions, especially in the cardiovascular and central nervous  
27 system.

28 A review by McLean et al. (McLean et al., 2020) drew our attention not only because it covers a timely  
29 and captivating topic, but because it clearly emphasizes serious limitations and methodological  
30 caveats regarding GLP-1 receptor (GLP-1R) expression analysis. Failure to acknowledge  
31 methodological caveats either willfully or through ignorance far too often leads to misinterpretation  
32 of the results and formation of unjustified conclusions challenging to rectify once they pass under the  
33 peer-review radar, and unfortunately – they often do. In this letter, we wish to acknowledge the  
34 intention of McLean et al. (McLean et al., 2020) to warn the readers about the methodological  
35 drawbacks, especially those regarding the specificity and sensitivity of GLP-1R antisera and  
36 supplement the „Caveats and limitations“ section (McLean et al., 2020) with our own experience and  
37 comment regarding bs-1559R anti-GLP-1R rabbit polyclonal antibody.

38 The problem of sensitivity and specificity of GLP-1R antibodies has already been brought up before  
39 and is probably best summarized by the statement that „scientists interested in GLP-1R expression  
40 face the challenging task of assessing how much, if any, of the data published with these antisera is  
41 correct“ (Drucker, 2013). Many anti-GLP-1R antibodies are commercially available but data  
42 demonstrating their specificity, selectivity, as well as „negative“ runs with cells or tissue samples from  
43 *Glp1r*<sup>-/-</sup> animals are usually not available even upon a reasonable request (Drucker, 2013). On the

44 other hand, problems are usually uncovered and reported by thoughtful end-users conducting  
45 validation experiments in the pursue of reliable data suitable to provide a meaningful representation  
46 of reality(Panjwani et al., 2013; Pyke and Knudsen, 2013). For example, Panjwani et al. demonstrated  
47 that three different commercially available antibodies – SantaCruz-sc-66911, LifeSpan-LS-A1205, and  
48 Abcam-ab39072 were unable to detect a difference in GLP-1R in lung extracts of *Glp1r*<sup>+/+</sup> and *Glp1r*<sup>-/-</sup>  
49 mice using a traditional Westen blot (WB) analysis (Panjwani et al., 2013). We have employed bs-  
50 1559R to detect GLP-1R with WB, immunohistochemistry, and catalyzed reported deposition in the  
51 rat tissue samples from pharmacological experiments with Exendin9-39. However, a closer look at the  
52 antibody specification makes us wonder whether the antibody raised to the keyhole limpet  
53 hemocyanine-conjugated synthetic peptide from 101-200/463 derived from the rat GLP-1R can give  
54 us the information we are looking for as i) the target epitope covers the orthosteric binding site, and  
55 ii) the immunogen sequence is highly dynamic and functionally important receptor domain? The  
56 transition of the GLP-1R to the active state requires a major conformational change of its extracellular  
57 domain (ECD) that has to reorient from the „closed“ transmembrane domain-interacting position to  
58 enable peptide binding (Wu et al., 2020). So far, the manufacturer was only able to confirm our  
59 suspicion regarding the orthosteric site-bound antibody affecting ligand binding. However, if vice  
60 versa is also true, could it be that e.g. ligand binding-induced conformational change of the ECD also  
61 affects our anti-GLP-1R-obtained signal? Could „conformational bias“ induced by convenient  
62 generation of antibodies to the conformationally dynamic „lid“ of GPCRs (Wheatley et al., 2012)  
63 explain at least some of the discrepant results on the GLP-1Rs, or even GPCRs in general(Pyke and  
64 Knudsen, 2013)? Either way, we should think about it and talk about it. We cannot afford to waste a  
65 good crisis (Drucker, 2016).

66 **Conflict of interest:** None.

67 **Author's contributions:** JH wrote the letter. ABP, AK, JOB, and MSP provided a critical feedback on  
68 the manuscript. All authors provided final approval of the version to be published.

69 **Funding source:** This work was funded by the Croatian Science Foundation (IP-2018-01-8938). The  
70 research was co-financed by the Scientific Centre of Excellence for Basic, Clinical, and Translational  
71 Neuroscience (project “Experimental and clinical research of hypoxic-ischemic damage in perinatal  
72 and adult brain”; GA KK01.1.1.01.0007 funded by the European Union through the European Regional  
73 Development Fund).

#### 74 **References:**

- 75 Drucker, D.J., 2016. Never Waste a Good Crisis: Confronting Reproducibility in Translational Research.  
76 *Cell Metab* 24, 348–360. <https://doi.org/10.1016/j.cmet.2016.08.006>
- 77 Drucker, D.J., 2013. Incretin action in the pancreas: potential promise, possible perils, and pathological  
78 pitfalls. *Diabetes* 62, 3316–3323. <https://doi.org/10.2337/db13-0822>
- 79 Drucker, D.J., Habener, J.F., Holst, J.J., 2017. Discovery, characterization, and clinical development of  
80 the glucagon-like peptides. *J Clin Invest* 127, 4217–4227. <https://doi.org/10.1172/JCI97233>
- 81 McLean, B.A., Wong, C.K., Campbell, J.E., Hodson, D.J., Trapp, S., Drucker, D.J., 2020. Revisiting the  
82 Complexity of GLP-1 Action from Sites of Synthesis to Receptor Activation. *Endocrine Reviews*.  
83 <https://doi.org/10.1210/endrev/bnaa032>
- 84 Panjwani, N., Mulvihill, E.E., Longuet, C., Yusta, B., Campbell, J.E., Brown, T.J., Streutker, C., Holland,  
85 D., Cao, X., Baggio, L.L., Drucker, D.J., 2013. GLP-1 receptor activation indirectly reduces  
86 hepatic lipid accumulation but does not attenuate development of atherosclerosis in diabetic  
87 male ApoE(-/-) mice. *Endocrinology* 154, 127–139. <https://doi.org/10.1210/en.2012-1937>
- 88 Pyke, C., Knudsen, L.B., 2013. The glucagon-like peptide-1 receptor--or not? *Endocrinology* 154, 4–8.  
89 <https://doi.org/10.1210/en.2012-2124>
- 90 Wheatley, M., Wootten, D., Conner, M., Simms, J., Kendrick, R., Logan, R., Poyner, D., Barwell, J., 2012.  
91 Lifting the lid on GPCRs: the role of extracellular loops. *Br J Pharmacol* 165, 1688–1703.  
92 <https://doi.org/10.1111/j.1476-5381.2011.01629.x>
- 93 Wu, F., Yang, L., Hang, K., Laursen, M., Wu, L., Han, G.W., Ren, Q., Roed, N.K., Lin, G., Hanson, M.A.,  
94 Jiang, H., Wang, M.-W., Reedtz-Runge, S., Song, G., Stevens, R.C., 2020. Full-length human  
95 GLP-1 receptor structure without orthosteric ligands. *Nature Communications* 11, 1272.  
96 <https://doi.org/10.1038/s41467-020-14934-5>
- 97